Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease

Kidney International

Volumn 53, Issue 3, 1998, Pages 726-734

  Zoja, Carla ^a   Corna, Daniela ^b   Benedetti, Giuditta ^b   Morigi, Marina ^b   Donadelli, Roberta ^b   Guglielmotti, Angelo ^b   Pinza, Mario ^b   Bertani, Tullio ^b   Remuzzi, Giuseppe ^b  

^a MARIO NEGRI INST PHARMACOL RES   (Italy)

^b NONE

Author keywords

Glomerular hypercellularity; Immunosuppression; Inflammation; Lupus nephritis; Monocyte chemoattractant protein 1; Murine lupus autoimmune disease

Indexed keywords

BINDARIT; METHYLPREDNISOLONE; MONOCYTE CHEMOTACTIC PROTEIN 1; PROPIONIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ADJUVANT ARTHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG MIXTURE; INFLAMMATION; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEINURIA; SURVIVAL RATE;

EID: 0031940491     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1998.00804.x     Document Type: Article

References (40)

1. HOWIE JR, HELVER BJ: The immunology and pathology of NZB mice. Adv Immunol 9:215-255, 1968
2. THEOFILOPOULOS AN, DIXON FJ: Etiopathogenesis of murine SLE. Immunol Rev 55:179-216, 1981
3. FOSTER MH, CIZMAN B, MADAIO MP: Nephritogenic autoantibodies in systemic lupus erythematosus: Immunochemical properties, mechanisms of immune deposition, and genetic origins. Lab Invest 69:494-503, 1993
4. TAX WJM, KRAMERS C, VAN BRUGGEN MCJ, BERDEN JHM: Apoptosis, nucleosomes, and nephritis in systemic lupus erythematosus. Kidney Int 48:666-673, 1995
5. LEFKOWITH JB, GILKESON GS: Nephritogenic autoantibodies in lupus. Current concepts and continuing controversies. Arthritis Rheum 39: 894-903, 1996
6. AUSTIN HA, BOUMPAS DT: Treatment of lupus nephritis. Semin Nephrol 16:527-535, 1996
7. BRENNAN DC, YUI MA, WUTHRICH RP, KELLEY VE: Tumor necrosis factor and IL-1 in New Zealand black/white mice. Enhanced gene expression and acceleration of renal injury. J Immunol 143:3470-3475, 1989
8. IWANO M, DOHI K, HIRATA E, HORII Y, SHIIKI H, ISHIKAWA H: Induction of interleukin 6 synthesis in mouse glomeruli and cultured mesangial cells. Nephron 62:58-65, 1992
9. GOTTI E, CASIRAGHI F, NORIS M, BENIGNI A, REMUZZI G: Enhanced urinary interleukin-6 (IL-6) and interleukin-1β (IL-1β) parallel renal disease activity in systemic lupus erythematosus (SLE). (abstract) J Am Soc Nephrol 5:749, 1994
10. IWANO M, DOHI K, HIRATA E, KURUMATANI N, HORII Y, SHIIKI H, FUKATSU A, MATSUDA T, HIRANO T, KISHIMOTO T, ISHIKAWA H: Urinary levels of IL-6 in patients with active lupus nephritis. Clin Nephrol 40:16-21, 1993
11. TAKEMURA T, YOSHIOKA K, MURAKAMI K, AKANO N, OKADA M, AYA N, MAKI S: Cellular localization of inflammatory cytokines in human glomerulonephritis. Virchows Arch 424:459-464, 1994
12. ZOJA C, LIU X-H, DONADELLI R, ABBATE M, TESTA D, CORNA D, TARABOLETTI G, VECCHI A, DONG QG, ROLLINS BJ, BERTANI T, REMUZZI G: Renal expression of monocyte chemoattractant protein-1 in lupus autoimmune mice. J Am Soc Nephrol 8:720-729, 1997
13. NORIS M, BERNASCONI S, CASIRAGHI F, SOZZANI S, GOTTI E, REMUZZI G, MANTOVANI A: Monocyte chemoattractant protein-1 is excreted in excessive amounts in the urine of patients with lupus nephritis. Lab Invest 73:804-809, 1995
14. WADA T, YOKOYAMA H, Su S-B, MUKAIDA N, IWANO M, DOHI K, TAKAHASHI Y, SASAKI T, FURUICHI K, SEGAWA C, HISADA Y, OHTA S, TAKASAWA K, KOBAYASHI K-I, MATSUSHIMA K: Monitoring urinary levels of monocyte chemotactic and activating factor reflects disease activity of lupus nephritis. Kidney Int 49:761-767, 1996
15. AUSTIN HA III, KLIPPEL JH, BALOW JE, LE-RICHE NG, STEINBERG AD, PLOTZ PH, DECKER JL: Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314:614-619, 1986
16. DONADIO JV, GLASSOCK RJ: Immunosuppressive drug therapy in lupus nephritis. Am J Kidney Dis 21:239-250, 1993
17. SEDOR JR: Interleukin-1: A master cytokine in the renal response to injury, in Molecular Nephrology. Kidney Function in Health and Disease, edited by SCHLONDORFF D, BONVENTRE JV, New York, Marcel Dekker, Inc., 1995, pp 631-652
18. POON M, MEGYESI J, GREEN RS, ZHANG H, ROLLINS BJ, SAFIRSTEIN R, TAUBMAN MB: In vivo and in vitro inhibition of JE gene expression by glucocorticoids. J Biol Chem 266:22375-22379, 1991
19. CORNA D, MORIGI M, FACCHINETTI D, BERTANI T, ZOJA C, REMUZZI G: Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease. Kidney Int 51:1583-1589, 1997
20. SASO L, SILVESTRINI B, ZWAIN I, GUGLIELMOTTI A, LUPARINI MR, CIOLI V, CHENG CY: Abnormal glycosylation of hemopexin in arthritic rats can be blocked by bindarit. J Rheumatol 19:1859-1867, 1992
21. CIOLI V, CIARNIELLO MG, GUGLIELMOTTI A, LUPARINI MR, DURANDO L, MARTINELLI B, CATANESE B, FAVA L, SILVESTRINI B: A new protein antidenaturant agent, bindarit, reduces secondary phase of adjuvant arthritis in rats. J Rheumatol 19:1735-1742, 1992
22. GUGLIELMOTTI A, SILVESTRINI B, SASO L, ZWAIN I, CHENG CY: Chronic inflammatory response in the rat can be blocked by bindarit. Biochem Mol Biol Int 29:747-756, 1993
23. GUGLIELMOTTI A, ROSIGNOLI MT, AQUILINI L, MILANESE C: Effects of bindarit in murine lupus disease. (abstract) Lupus 4:115, 1995
24. STEINBERG AD, GELFAND MC, HARDIN JA, LOWENTHAL DT: Therapeutic studies in NZB/W mice. III. Relationship between renal status and efficacy of immunosuppressive drug therapy. Arthritis Rheum 18:9-14, 1975
25. GELFAND MC, STEINBERG AD, NAGLE R, KNEPSHIELD JH: Therapeutic studies in NZB/W mice. I. Synergy of azathioprine, cyclophosphamide and methylprednisolone in combination. Arthritis Rheum 15: 239-246, 1972
26. READ SM, NORTHCOTE DH: Minimization of variation in the response to different proteins of the Coomassie blue G dye-binding assay for protein. Anal Biochem 116:53-64, 1981
27. RAMBALDI A, YOUNG DC, GRIFFIN ID: Expression of the M-CSF (CSF-1) gene by human monocytes. Blood 69:1409-1413, 1987
28. ROLLINS BJ, MORRISON ED, STILES CD: Cloning and expression of JE, a gene inducible by platelet-derived growth factor and whose product has cytokine-like properties. Proc Natl Acad Sci USA 85: 3738-3742, 1988
29. FEINBERG AP, VOLGESTEIN B: A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem 132:6-13, 1983
30. NORIS M, MORIGI M, DONADELLI R, AIELLO A, FOPPOLO M, TODESCHINI M, ORISIO S, REMUZZI G, REMUZZI A: Nitric oxide synthesis by cultured endothelial cells is modulated by flow conditions. Circ Res 76:536-543, 1995
31. FORTH P, MARTY L, PIECHACZY KM, EL SABROUTY S, DANI C, JEANTEUR P, BLANCHARD JM: Various rat adult tissues express only one major mRNA species from the glyceraldehyde 3-phosphatedehydrogenase multigenic family. Nucleic Acids Res 13:1431-1432, 1985
32. BALOW JE: Lupus nephritis. Ann Intern Med 106:79-94, 1987
33. MCGIVEN AR, LYNRAVEN GS: Glomerular lesions in NZB/NZW mice: Electron microscopic study of development. Arch Pathol 85: 250-261, 1968
34. ALEXOPOULUS E, SERON D, HARTLEY RB, CAMERON S: Lupus nephritis: Correlation of interstitial cells with glomerular function. Kidney Int 37:100-109, 1990
35. D'AGATI VD, APPEL GB, ESTES D, KNOWLES II, PIRANI CL: Monoclonal antibody identification of infiltrating mononuclear leukocytes in lupus nephritis. Kidney Int 30:573-581, 1986
36. CARR MW, ROTH SJ, LUTHER E, ROSE SS, SPRINGER TA: Monocyte chemoattractant protein-1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci USA 91:3652-3656, 1994
37. TAUB DD, PROOST P, MURPHY WJ, ANVER M, LONGO DL, VAN DAMME J, OPPENHEIM JJ: Monocyte chemotactic protein-1 (MCP-1), -2, and -3 are chemotactic for human T lymphocytes. J Clin Invest 95:1370-1376, 1995
38. LEONARD EJ, YOSHIMURA T: Human monocyte chemoattractant protein-1 (MCP-1). Immunol Today 11:97-101, 1990
39. GUGLIELMOTTI A, ROMANO M, COLETTA I, VECCHI A, POLENTARUTTI N, MILANESE C, MANTOVANI A, PINZA M: Bindarit effects on MCP-1 and IL-6: A potential mechanism for renal injury protection. (abstract) J Am Soc Nephrol 8:473, 1997
40. VIGANO G, GOTTI E, CASIRAGHI F, NORIS M, TADDEI I, DIONISIO P, REMUZZI G: Bindarit reduces urinary albumin excretion (UAE) and urinary interlcukin-6 (IL-6) in patients with proliferative lupus nephritis. (abstract) J Am Soc Nephrol 6:434, 1995